PriceTargets.com logo

Alliance Pharma - APH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 102.50
  • Forecasted Upside: 48.55%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
GBX 69 As of 03/31/2023 01:00 AM ET
▲ +1 (1.47%)

This chart shows the closing price for APH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alliance Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APH

Analyst Price Target is GBX 102.50
▲ +48.55% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Alliance Pharma in the last 3 months. The average price target is GBX 102.50, with a high forecast of GBX 130 and a low forecast of GBX 65. The average price target represents a 48.55% upside from the last price of GBX 69.

This chart shows the closing price for APH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Alliance Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/17/2023Peel HuntInitiated CoverageHoldGBX 65
2/1/2023Numis SecuritiesReiterated RatingBuyGBX 110
1/17/2023Berenberg BankLower TargetBuyGBX 110 ➝ GBX 105
9/20/2022Berenberg BankReiterated RatingBuyGBX 145
8/8/2022Royal Bank of CanadaReiterated RatingOutperformGBX 130
7/14/2022Berenberg BankReiterated RatingBuyGBX 145
6/15/2022Berenberg BankReiterated RatingBuyGBX 145
3/24/2022Royal Bank of CanadaReiterated RatingOutperformGBX 130
1/28/2022Royal Bank of CanadaBoost TargetOutperformGBX 106 ➝ GBX 121
6/29/2021Numis SecuritiesReiterated RatingBuyGBX 120
6/3/2019Numis SecuritiesReiterated RatingBuy
5/24/2019Numis SecuritiesReiterated RatingBuyGBX 115
5/16/2019Numis SecuritiesReiterated RatingBuy
5/1/2019Numis SecuritiesUpgradeBuy
4/10/2019Numis SecuritiesReiterated RatingBuyGBX 115
1/21/2019Numis SecuritiesUpgradeBuyGBX 115
9/19/2018Numis SecuritiesReiterated RatingAddGBX 115
7/13/2018Numis SecuritiesBoost TargetAddGBX 99 ➝ GBX 115
6/7/2018Numis SecuritiesDowngradeAddGBX 88 ➝ GBX 99
4/17/2018Numis SecuritiesBoost TargetBuyGBX 80 ➝ GBX 88
(Data available from 4/1/2018 forward)

News Sentiment Rating

-0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/31/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Alliance Pharma logo
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.
Read More

Today's Range

Now: GBX 69
Low: 68
High: 69.40

50 Day Range

MA: GBX 65.19
Low: 57.60
High: 71.70

52 Week Range

Now: GBX 69
Low: 34.14
High: 122

Volume

2,490,117 shs

Average Volume

2,431,327 shs

Market Capitalization

£372.60 million

P/E Ratio

3,450.00

Dividend Yield

2.99%

Beta

0.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Alliance Pharma?

The following Wall Street sell-side analysts have issued reports on Alliance Pharma in the last twelve months: Berenberg Bank, Numis Securities Ltd, Peel Hunt, and Royal Bank of Canada.
View the latest analyst ratings for APH.

What is the current price target for Alliance Pharma?

4 Wall Street analysts have set twelve-month price targets for Alliance Pharma in the last year. Their average twelve-month price target is GBX 102.50, suggesting a possible upside of 48.6%. Royal Bank of Canada has the highest price target set, predicting APH will reach GBX 130 in the next twelve months. Peel Hunt has the lowest price target set, forecasting a price of GBX 65 for Alliance Pharma in the next year.
View the latest price targets for APH.

What is the current consensus analyst rating for Alliance Pharma?

Alliance Pharma currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APH will outperform the market and that investors should add to their positions of Alliance Pharma.
View the latest ratings for APH.

What other companies compete with Alliance Pharma?

Other companies that are similar to Alliance Pharma include MaxCyte, Oxford Biomedica, Horizon Discovery Group plc (HZD.L), Avacta Group and Amryt Pharma. Learn More about companies similar to Alliance Pharma.

How do I contact Alliance Pharma's investor relations team?

Alliance Pharma's physical mailing address is Avonbridge House, Bath Road, CHIPPENHAM, SN15 2BB, United Kingdom. The company's listed phone number is +44-1249-466966. The official website for Alliance Pharma is www.alliancepharma.co.uk. Learn More about contacing Alliance Pharma investor relations.